The Shot You Take Once a Quarter That Could Reshape Myasthenia Gravis

At week 24, cemdisiran patients improved by 4.5 points versus 2.2 points for placebo. That placebo-adjusted difference of 2.3 points hit statistical significance at p<0.001. More impressively, 76.6% of cemdisiran patients achieved a clinically meaningful response (at least a 3-point improvement), compared to just 44.1% on placebo.

The secondary endpoint told the same story. The QMG score (a physician-assessed measure of muscle weakness) improved by 4.2 points with cemdisiran versus 1.5 with placebo. Nearly half of cemdisiran patients hit the 5-point QMG threshold; only 19% of placebo patients did.

Perhaps most notable: improvements showed up within two weeks and held steady through week 24, with no sign of the drug wearing off between quarterly doses.

The Safety Surprise

Complement inhibitors carry an inherent worry: if you suppress part of the immune system's rapid-response team, are you inviting serious infections? In NIMBLE, the answer was reassuring. Cemdisiran patients actually reported fewer adverse events than the placebo group (69% versus 77%). There were no serious infections, no meningococcal events, and no deaths during the blinded treatment period. The most common side effect was upper respiratory tract infections at 12%, essentially matching placebo's 11%.

This safety profile matters because cemdisiran only achieves about 74% complement inhibition, not the near-complete blockade you'd get with an antibody. In gMG, that partial suppression turns out to be a feature rather than a bug: enough to treat the disease, not so much that you're leaving patients immunologically exposed.

The "Less Is More" Strategy

Regeneron actually tested two approaches in NIMBLE: cemdisiran alone (partial C5 blockade) and cemdisiran combined with pozelimab, their anti-C5 antibody (near-complete blockade). The counterintuitive finding? Monotherapy performed numerically better than the combination. The Lancet publication confirmed both were effective, but the simpler, less aggressive approach won on the scoreboard.

This insight shapes Regeneron's entire complement strategy. For gMG, they're filing cemdisiran as a monotherapy. For paroxysmal nocturnal hemoglobinuria (PNH), where red blood cells are actively destroyed and you need every last bit of C5 neutralized, they'll use the full cemdisiran-plus-pozelimab combination. Phase 3 PNH data are expected in late 2026, potentially giving Regeneron two complement approvals from the same modular platform.

A Crowded Bar, But a Different Drink

The gMG market is no sleepy backwater. Soliris (eculizumab) and Ultomiris (ravulizumab) dominate the C5 inhibitor class but require IV infusions. Zilbrysq (zilucoplan) offers daily subcutaneous C5 inhibition. And then there's Vyvgart, an FcRn inhibitor from argenx that isn't even a complement drug but keeps stealing patients from the C5 camp because it works well and is convenient.

Cemdisiran's differentiator is pure simplicity: one shot, every three months, at home. No infusion centers. No daily injections. No IV lines.

Analysts are split on whether that's enough. Truist Securities said cemdisiran "surpassed our expectations" based on historical anti-C5 performance and argued its dosing schedule could help it "capture a significant share of the C5 gMG market." But Leerink's David Risinger was more cautious, noting that cemdisiran's efficacy appears to "fall short" of some FcRn-blocking therapies.

What November Means

The FDA's Priority Review designation (Regeneron used a Priority Review Voucher to secure it) compresses the review timeline and signals that the agency sees potential for meaningful therapeutic advancement. An approval in November 2026 would give Regeneron a commercial launch window into a market that's growing fast but fragmenting faster.

The EMA has also accepted Regeneron's application, with a European decision expected in the second half of 2027.

For patients with gMG who currently sit in infusion chairs every few weeks, or self-inject daily, or cycle through immunosuppressants with inconsistent results, a quarterly shot that works within two weeks and maintains its effect between doses sounds less like incremental progress and more like a genuinely different treatment experience.

Whether Wall Street rewards "different" or demands "best" will determine how this story ends. But the FDA, at least, is interested enough to fast-track the answer.

Exelixis Built a Backup Plan for Its $2B Drug. It Just Hit a Wall.

Exelixis' next-generation drug zanzalintinib missed a key survival endpoint in colorectal cancer, sending shares down 10-12%. With Cabometyx still driving 90% of revenue, the pressure to prove the successor can carry the franchise just got a lot more intense.